​

Funding Round

Series A - Triumvira Immunologics

Series A - Triumvira Immunologics

Investment Firm

Overview

Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.

Announced Date

Mar 17, 2022

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

B Capital

B Capital

B Capital is a early_stage_venture and grant and late_stage_venture and venture firm.

Participant Investors

5

Investor Name
Participant InvestorATEM Capital Fund LP
Participant InvestorMyeloma Investment Fund
Participant InvestorLeaps by Bayer
Participant InvestorMultiple Myeloma Research Foundation
Participant InvestorB Capital

Round Details and Background

Triumvira Immunologics raised $45000000 on 2022-03-17 in Series A

Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 27, 2020
Series A - Triumvira Immunologics
6-55.0M
Mar 17, 2022
Series A - Triumvira Immunologics
6-45.0M

Recent Activity

There is no recent news or activity for this profile.